Adaptimmune Therapeutics PLC Logo

Adaptimmune Therapeutics PLC

Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.

ADAP | US

Overview

Corporate Details

ISIN(s):
US00653A1079
LEI:
Country:
United States of America
Address:
60 JUBILEE AVENUE, 0 ABINGDON, OXFORDSHIRE

Description

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Adaptimmune Therapeutics PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adaptimmune Therapeutics PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adaptimmune Therapeutics PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharmaceutical company developing combination therapies for cancer.
United States of America
RCUS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.